23 October 2024
Read More3 October 2024
Read More26 September 2024
Read MoreWe are a family of strong 800+ people including 470+ professionals working from 14 locations across India.
We have a rich heritage and enduring legacy which are pivotal in shaping trust, excellence, and unparalleled legal expertise, thus building a strong reputation and a trusted brand.
Read MoreWe started in 1985 in a single room set up by the two founders with no prior experience of working in a law firm. Both the founders had outstanding academic records and focused on their deep understanding of the law to form the foundation of the firm.
Integrity, Knowledge and Passion are the principles that resonate with every member of our LKS family and the work that we do. These values drive us to build a community of legally sound professionals and well-serviced clients.
Everything we have accomplished over the last four decades is a result of our unique way of thinking which is deeply influenced by our core values and principles that define us.
Read MoreWe and our professionals consistently garner appreciation for the quality of our services and the depth of our legal expertise. This consistent acknowledgment serves as a testament to our unwavering commitment to exceed expectations.
Two co-ordinate Single Judge Benches of the Delhi High Court have recently arrived at opposing conclusions as to whether to grant interim injunction or not in favour of the Plaintiffs/Patentee in a batch of patent infringement suits in relation to a pharmaceutical composition. Analysing the two decisions threadbare, the author states that the question as to what constitutes “Coverage” and “Disclosure” in the context of genus and species patent is still uncertain, and that the determination of the distinction between these two terms, which is the core of the instant patent infringement suits, will most likely be for most pharmaceutical product inventions. According to the author, even the issue as to what constitutes credible challenge to the validity of the suit patent to warrant denial of interim injunction, is very subjective. The author in this regard also highlights another recent decision of the Court which also hinges on genus vs. species patent disclosure and coverage, disclosures in Form 27 and admissions in corresponding foreign litigations…
The article in this issue of IPR Amicus, while exploring the subject, analyses various case...
The decision focused on two pivotal issues - whether the enhanced bioavailability data could be...
Get access to our latest newsletters, articles and events:
Scan the QR code to get in
touch with us